Immune-Mediated Neuropathy Pipeline — PatSnap Eureka
Immune-Mediated Neuropathy Pipeline: FcRn & Complement Approaches in CIDP, GBS & MMN
Pathogenic autoantibodies targeting nodal and paranodal proteins drive CIDP, GBS, and MMN. A new generation of FcRn antagonists and complement inhibitors is challenging the non-specific standard of care — and defining the next wave of seropositive patient stratification.
Autoantibody-Driven Peripheral Nerve Disorders: Shared Biology, Distinct Subtypes
Peripheral neuropathy drug discovery is increasingly driven by autoantibody serotyping. CIDP, GBS, and MMN represent a spectrum of immune-mediated peripheral nerve disorders in which both humoral and cellular immunity contribute to nerve injury, with relative contributions differing by disease subtype and patient serotype.
Nodal and paranodal autoantibodies are a prominent focus across retrieved patent and literature records. Antibodies against neurofascin-155 (NF155), neurofascin-186 (NF186), contactin-1 (CNTN1), contactin-associated protein 1 (Caspr1/CNTN1R), and pan-neurofascin epitopes have been identified in subsets of CIDP and GBS patients. These autoantibodies target proteins at the node of Ranvier, interfering with saltatory conduction and constituting a defined seropositive CIDP population with distinct clinical features and often suboptimal responses to standard IVIg therapy.
Anti-ganglioside antibodies (particularly anti-GM1 IgM) are detected in approximately 50% of MMN patients and are implicated in conduction block at nodes of Ranvier. In GBS, anti-ganglioside antibodies activating complement at axonal membranes underpin the acute motor axonal neuropathy (AMAN) variant. WHO recognizes GBS as a rapidly evolving condition requiring urgent clinical attention.
Anti-MAG IgM paraproteinemic neuropathy involves IgM antibodies against myelin-associated glycoprotein with complement deposition on the myelin sheath — a mechanism directly invoked in patent claims from Alexion Pharmaceuticals for complement inhibition. The IP analytics landscape for these indications is rapidly evolving.
A 2023 paper from International University of Health and Welfare, Fukuoka, identifies anti-LGI4 as a novel juxtaparanodal autoantibody in CIDP patients seronegative for anti-NF155 and anti-CNTN1, demonstrating ongoing discovery of new target antigens that may define further treatable subsets.
Seroprevalence & Complement Target Coverage Across Indications
Key quantitative signals from the patent and literature dataset, visualised from retrieved records via PatSnap Eureka.
Anti-NF155 IgG4 Seroprevalence in CIDP Cohorts
Meta-analysis (China Medical University) reports 9% pooled sensitivity with 100% specificity; Kyushu University consecutive cohort shows 18% positivity — all uniformly IgG4 subclass.
Complement Inhibition: Pathway Coverage by Target
Anti-C2 (argenx) blocks both classical and lectin pathways upstream; anti-C5 (Alexion) targets terminal MAC formation; anti-C1q (University of Glasgow) offers superior tissue specificity in ganglioside-rich motor nerves.
Emerging Pipeline Approaches: FcRn, Complement, BTK, and Beyond
Six therapeutic modalities are active or emerging in this dataset, spanning patent-driven commercial entities and academic preclinical work. Standard-of-care IVIg/SCIg serves as the benchmark comparator.
FcRn Antagonism (Anti-FcRn Antibodies)
Anti-FcRn antibodies block the neonatal Fc receptor, accelerating catabolism of all IgG subclasses including pathogenic anti-NF155, anti-CNTN1, and anti-GM1 autoantibodies. Patent analytics reveal Immunovant Sciences GmbH holds two active/pending IL-jurisdiction patents (2025) with a September 2022 priority date, specifically claiming anti-FcRn antibody methods for CIDP treatment. IgG4 subclass predominance in anti-NF155 CIDP means FcRn-mediated depletion is mechanistically more relevant than complement inhibition for this subtype, as IgG4 does not fix complement.
Immunovant Sciences GmbH · 2 patents · 2025Complement Pathway Inhibition (C5, C2, C1q)
Three distinct intervention points: Anti-C5 (Alexion) — active EP patent (2016) covering GBS, AMAN, CIDP, anti-MAG neuropathy via MAC prevention. Anti-C2 (argenx) — active EP patent (2025) blocking both classical and lectin pathways; explicitly names MMN, CIDP, and GBS. Anti-C1q (University of Glasgow) — preclinical AMAN mouse model data showing superior tissue specificity versus C5 inhibition at ganglioside-rich motor nerve nodes. The EPO portfolio for complement inhibitors in neuropathy spans 2012–2025.
Alexion · argenx · University of GlasgowBTK Inhibition (Tirabrutinib)
A case report from Juntendo University School of Medicine describes successful treatment of rituximab-refractory anti-MAG neuropathy with tirabrutinib, a second-generation Bruton's tyrosine kinase (BTK) inhibitor, providing an early clinical signal for BTK inhibition in paraproteinemic neuropathy at 11 months of follow-up. Combined with the known role of B cells and plasma cells in generating IgG4 paranodal autoantibodies, BTK inhibition represents an emerging upstream strategy complementary to FcRn and complement approaches.
Juntendo University · 11-month sustained responseSubcutaneous Immunoglobulin (SCIg / IVIg)
IVIg and SCIg remain the standard of care against which emerging therapies are evaluated. The PATH trial (van Schaik et al., Lancet Neurology 2018), referenced in a Wayne State University appraisal, demonstrated that subcutaneous immunoglobulin is an effective maintenance therapy for CIDP. Multiple IVIg mechanisms are described: complement inhibition, FcγR saturation, anti-idiotypic antibody effects, and Fc-mediated receptor modulation. UMC Utrecht literature covers IVIg in MMN. Despite phase 3 efficacy, seropositive patients — particularly anti-NF155 IgG4 — characteristically fail IVIg.
PATH trial · Phase 3 · Wayne State / UMC UtrechtS1P Receptor Agonists & MS Disease-Modifying Therapies
FTY720 (fingolimod), an S1P receptor agonist depleting peripheral lymphocytes, demonstrated disease control in a chronic experimental autoimmune neuritis (c-EAN) rat model at the University of Strasbourg. However, fingolimod was not effective in the SAPP mouse model, highlighting model-dependent limitations. A University of Cologne review (2023) discusses repurposing MS DMTs — including natalizumab, ocrelizumab, and ofatumumab — for CIDP, citing pathogenesis homologies. Novartis AG holds an inactive 2012 IL patent on S1P-related immunosuppressant scaffolds for demyelinating peripheral neuropathy.
University of Strasbourg · Novartis (inactive) · Cologne 2023Apheresis / Immunoadsorption — Demonstrating the Gap
A University of Ulm clinical study of immunoadsorption (IA) and plasma exchange (PLEx) in seropositive inflammatory neuropathy found that, despite transient antibody suppression, no patients in a 41-patient cohort achieved a good response as rated by treating clinicians. This underscores the therapeutic gap that motivates FcRn antagonism and targeted complement inhibition as alternatives to non-specific antibody reduction strategies. The NIH/NINDS recognizes CIDP as an area of active therapeutic investigation.
University of Ulm · 41 patients · 0 good responsesCommercial Assignees: Patent Activity in CIDP, GBS & MMN
Innovation activity bifurcates between commercial patent-driven entities focused on FcRn and complement modalities, and academic literature-driven centres focused on disease biology and biomarker development.
| Assignee | Modality | Target Indication(s) | Patent Status | Jurisdiction / Year |
|---|---|---|---|---|
| Immunovant Sciences GmbH (Basel, Switzerland) | Anti-FcRn antibody | CIDP | Pending | IL · 2025 (priority Sep 2022) |
| argenx BVBA (Ghent, Belgium) | Anti-C2 complement antagonist | MMN, CIDP, GBS, paraproteinemic neuropathies | Active | EP · 2025 |
| Alexion Pharmaceuticals, Inc. (New Haven, USA) | Anti-C5 antibody / complement inhibitor | GBS, AMAN, CIDP, anti-MAG neuropathy | Active | EP · 2016 |
| Alexion Pharmaceuticals, Inc. (New Haven, USA) | Anti-C5 antibody / complement inhibitor | Antibody-mediated neuropathies | Inactive | IL · 2012 |
| KU Leuven / KU Leuven R&D (Leuven, Belgium) | sNfL prognostic biomarker | CIDP (therapy response / disease progression) | Active | EP · 2024 |
| Biogen MA Inc. (Cambridge, USA) | IFN-β therapeutics | CIDP | Inactive | IL · 2006 |
| Novartis AG (Basel, Switzerland) | S1P-related immunosuppressants | Demyelinating peripheral neuropathy | Inactive | IL · 2012 |
| Vaccinex, Inc. (Rochester, USA) | CXCL13-binding molecules | Peripheral nerve regeneration (adjacent) | Active | JP · 2025 |
Map competitive IP positions across FcRn and complement modalities
PatSnap Eureka surfaces assignee landscapes, claim overlaps, and white-space opportunities for any neuropathy target.
Clinical & Translational Evidence: What the Dataset Reveals
Seven translational signals are identified across retrieved patent and literature records, spanning phase 3 benchmarks, IND-enabling preclinical data, and emerging biomarker evidence.
Phase 3 SCIg Benchmark (PATH Trial)
The PATH trial (van Schaik et al., Lancet Neurology 2018), referenced in a Wayne State University appraisal, demonstrated that subcutaneous immunoglobulin is an effective maintenance therapy for CIDP, providing the phase 3 benchmark against which FcRn and complement candidates will be evaluated.
Anti-FcRn (Immunovant) in CIDP — Active Development
Two pending IL patents from Immunovant Sciences GmbH (priority September 2022) describe clinical methods of treating CIDP with anti-FcRn antibodies, including specific dosing and patient stratification strategies. Their pending status and recent priority date are consistent with ongoing clinical development, though no trial outcome data appear in the retrieved records.
Seropositive Patient Stratification for Trial Design
Multiple clinical cohort studies identify seropositive subgroups — anti-NF155 IgG4, anti-CNTN1 IgG4, and anti-pan-NF IgG3 — with defined treatment response profiles. Anti-NF155 IgG4 patients characteristically fail IVIg; anti-pan-NF IgG3 patients have high mortality. These findings directly inform patient selection for FcRn and complement trials.
sNfL as Pharmacodynamic Biomarker
Retrospective and prospective clinical studies (Toyama University, KU Leuven, London National Hospital) demonstrate that serum neurofilament light chain (sNfL) levels fall with IVIg treatment in CIDP and correlate with disease activity. A KU Leuven EP patent claims sNfL for prognostic use in CIDP. This biomarker is positioned to serve as a pharmacodynamic endpoint in future FcRn and complement trials, potentially accelerating go/no-go decisions and reducing trial size requirements.
What the Pipeline Signals Mean for Drug Developers
FcRn antagonism is the most IP-active emerging modality in this dataset. Immunovant Sciences GmbH holds two pending patents specifically for anti-FcRn antibodies in CIDP with a 2022 priority date. argenx, with its existing FcRn antagonist efgartigimod, is simultaneously pursuing complement pathway IP (anti-C2). Organizations not holding FcRn IP in CIDP face a narrowing window for freedom-to-operate, particularly given the well-characterized seropositive subpopulations that can anchor clinical enrichment strategies.
Complement inhibition requires modality selection precision. Retrieved results reveal three distinct complement intervention points (C1q, C2, C5/C5a) with different efficacy profiles across GBS variants, CIDP, and MMN. Anti-C2 (argenx, active EP 2025) covers both classical and lectin pathways and represents a mechanistically broader claim than C5-only approaches. The patent analytics landscape suggests drug developers should evaluate upstream versus downstream complement targeting based on the specific autoantibody isotype and effector mechanism in each target indication.
The unmet need in MMN remains underaddressed. Whereas CIDP and GBS are the primary named indications in retrieved FcRn and complement patents, MMN — despite shared pathophysiology involving anti-GM1 complement-fixing IgM antibodies — is less prominently featured as a standalone indication. The argenx anti-C2 patent explicitly names MMN as a target; this represents a potential first-mover IP position for complement inhibition specifically in MMN, where more than 80% of patients respond to IVIg but slowly progressive axonal degeneration continues despite treatment.
The PatSnap customer network includes leading biopharma organizations using Eureka to identify white-space opportunities in autoimmune neurology. PatSnap's API enables programmatic access to the full patent and literature dataset for computational drug discovery teams. The EMA regulatory framework for orphan designations in rare neuropathies may provide development incentives for seropositive CIDP subpopulations.
Assignee Patent Activity: 2006–2025
Timeline of key patent filings across FcRn, complement, and immunomodulatory modalities, showing the shift from inactive early-stage approaches to active FcRn and upstream complement strategies.
Patent Filing Timeline by Assignee and Modality (2006–2025)
Active patents concentrate in 2024–2025 (Immunovant FcRn, argenx anti-C2, KU Leuven sNfL, Vaccinex CXCL13); inactive patents cluster in 2006–2012 (Biogen IFN-β, Novartis S1P, Alexion early C5). Alexion's 2016 EP anti-C5 patent remains active.
Immune-Mediated Neuropathy Pipeline — Key Questions Answered
Anti-FcRn antibodies act by blocking the neonatal Fc receptor, which normally recycles IgG antibodies and extends their serum half-life. Blockade of FcRn accelerates catabolism of all IgG subclasses, including pathogenic autoantibodies such as anti-NF155, anti-CNTN1, and anti-GM1. In CIDP — where IgG4 (and occasionally IgG3) autoantibodies directed at paranodal proteins are established as pathogenic — FcRn antagonism offers a mechanistically rational approach to reduce autoantibody titers.
Alexion Pharmaceuticals holds an active EP-jurisdiction patent (2016) claiming anti-C5 antibodies for antibody-mediated neuropathies including GBS, AMAN, CIDP, and anti-MAG neuropathy. argenx BVBA holds an active EP patent (2025) claiming anti-C2 complement antagonists for paraproteinemic neuropathies including MMN, CIDP, and GBS. Immunovant Sciences GmbH holds two active/pending IL-jurisdiction patents (2025) specifically claiming anti-FcRn antibody methods for CIDP treatment.
A meta-analysis from the First Affiliated Hospital of China Medical University identified anti-NF155 IgG4 antibodies in approximately 9% of CIDP patients, with 100% specificity. A Kyushu University study found 18% positivity for anti-NF155 in a consecutive CIDP cohort, uniformly IgG4 subclass.
Anti-NF155 IgG4, anti-CNTN1 IgG4, and anti-pan-NF IgG3 subtypes have radically different biology, prognoses, and predicted responses to FcRn versus complement inhibition. IgG4 subclass predominance is therapeutically significant: IgG4 does not fix complement, suggesting FcRn-mediated IgG depletion is mechanistically more relevant than complement inhibition for this subtype. Anti-IgG4 disease may be more responsive to FcRn than complement inhibition, while IgG3/IgG1 complement-fixing antibodies make patients candidates for both FcRn and complement approaches.
Retrospective and prospective clinical studies demonstrate that serum neurofilament light chain (sNfL) levels fall with IVIg treatment in CIDP and correlate with disease activity. A KU Leuven EP patent claims sNfL for prognostic use in CIDP. This biomarker is positioned to serve as a pharmacodynamic endpoint in future FcRn and complement trials, and could accelerate go/no-go decisions and reduce trial size requirements.
More than 80% of MMN patients respond to IVIg, but slowly progressive axonal degeneration continues despite treatment. MMN is less prominently featured as a standalone indication in retrieved FcRn and complement patents. The argenx anti-C2 patent explicitly names MMN as a target, representing a potential first-mover IP position for complement inhibition specifically in MMN.
Still have questions? Let PatSnap Eureka search the neuropathy patent literature for you.
Ask PatSnap Eureka Your Pipeline QuestionsAccelerate Your Immune-Mediated Neuropathy Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to map FcRn, complement, and autoantibody patent landscapes — and identify the white-space opportunities your pipeline needs.
References
- Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy — University Hospital Würzburg, 2018
- Impact of Neurofascin on Chronic Inflammatory Demyelinating Polyneuropathy via Changing the Node of Ranvier Function: A Review — Karolinska Institute, 2021
- Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis — First Affiliated Hospital of China Medical University, 2018
- Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy — Kyushu University, 2015
- Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy — UMC Utrecht, 2010
- MMN: From Immunological Cross-Talk to Conduction Block — UMC Utrecht Brain Center Rudolf Magnus, 2014
- C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy — University of Glasgow, 2016
- Methods and compositions for the treatment of antibody mediated neuropathies — Alexion Pharmaceuticals, Inc., 2016 (EP active)
- Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies — argenx BVBA, 2025 (EP active)
- Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives — Dompé Farmaceutici SpA, 2021
- Methods of treating chronic inflammatory demyelinating polyneuropathy using Anti-FcRn antibodies — Immunovant Sciences GmbH, 2025 (IL pending)
- Methods of treating chronic inflammatory demyelinating polyneuropathy using Anti-FcRn antibodies — Immunovant Sciences GmbH, 2025 (IL pending)
- Subcutaneous immunoglobulin proves to be an effective alternative to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyneuropathy — Wayne State University, 2020
- Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model — UCB Pharma, 2022
- Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib — Juntendo University School of Medicine, 2022
- FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis — University of Strasbourg, 2019
- Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies — University of Ulm, 2020
- Guillain-Barré Syndrome — World Health Organization (WHO)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — NIH/NINDS
- European Patent Office (EPO) — Patent database and regulatory framework
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.